EV/EBITDA | 2026-04-23 | Quality Score: 92/100
Expert US stock fundamental screening criteria and quality metrics to identify companies with durable competitive advantages and sustainable business models. Our fundamental analysis goes beyond simple ratios to understand the true drivers of long-term business value and profitability. We provide quality scores, economic moat analysis, and competitive positioning tools for comprehensive evaluation. Find quality companies with our comprehensive fundamental screening and expert analysis for long-term investment success.
This report analyzes the bullish investment thesis for CVS Health (CVS), a U.S. integrated healthcare provider that has underperformed the S&P 500 on a total return basis year-to-date 2026, with shares down more than 3% as of April 22, 2026. We evaluate the market’s mispricing of the firm’s multi-ye
Live News
Published at 11:40 UTC on April 22, 2026, this update comes as CVS Health (CVS) trades 3.2% lower year-to-date, lagging the S&P 500’s 8.1% total return over the same period, leading many market participants to categorize the firm as a mature, low-growth healthcare staple. Earlier this month, the Centers for Medicare and Medicaid Services (CMS) announced a 2.48% increase in 2026 Medicare payment rates, well above initial consensus estimates of a 0.9% rise, a material positive catalyst for CVS’s A
CVS Health (CVS) – Deep Value Opportunity Amid Underappreciated Integrated Healthcare TransformationReal-time data enables better timing for trades. Whether entering or exiting a position, having immediate information can reduce slippage and improve overall performance.Cross-market analysis can reveal opportunities that might otherwise be overlooked. Observing relationships between assets can provide valuable signals.CVS Health (CVS) – Deep Value Opportunity Amid Underappreciated Integrated Healthcare TransformationAnalytical dashboards are most effective when personalized. Investors who tailor their tools to their strategy can avoid irrelevant noise and focus on actionable insights.
Key Highlights
Core fundamental and valuation highlights supporting the bullish thesis for CVS include the following: First, the stock trades at a forward price-to-earnings (P/E) ratio of 10.8x, a 45% discount to the S&P 500’s 19.7x forward P/E, despite consistent top-line growth: 10-year revenue growth of 126.5%, 2025 full-year revenue of $402.1 billion (up 7.8% year-over-year), and adjusted diluted earnings per share (EPS) of $6.75 (up 24.5% year-over-year). Management has guided for 2026 adjusted EPS of $7.
CVS Health (CVS) – Deep Value Opportunity Amid Underappreciated Integrated Healthcare TransformationReal-time data analysis is indispensable in today’s fast-moving markets. Access to live updates on stock indices, futures, and commodity prices enables precise timing for entries and exits. Coupling this with predictive modeling ensures that investment decisions are both responsive and strategically grounded.Analyzing trading volume alongside price movements provides a deeper understanding of market behavior. High volume often validates trends, while low volume may signal weakness. Combining these insights helps traders distinguish between genuine shifts and temporary anomalies.CVS Health (CVS) – Deep Value Opportunity Amid Underappreciated Integrated Healthcare TransformationScenario analysis based on historical volatility informs strategy adjustments. Traders can anticipate potential drawdowns and gains.
Expert Insights
From a valuation perspective, CVS’s current forward P/E multiple implies the market is pricing in perpetual low single-digit earnings growth, a narrative that fails to account for the firm’s integrated healthcare moat, which is not replicable by pure-play pharmacy retailers or standalone health insurers. The firm’s 1,000+ walk-in clinics, including MinuteClinics and 230 senior-focused Oak Street Health centers, create a closed-loop ecosystem that drives higher medication adherence rates for Aetna members, reduces avoidable hospital admissions, and lowers overall medical costs for the insurance segment, creating a self-reinforcing efficiency flywheel that is still in the early stages of scaling. While the low-margin retail pharmacy segment has historically weighed on CVS’s valuation multiple, the ongoing contraction of competing pharmacy footprints from Rite Aid’s bankruptcy will allow CVS to raise prescription dispensing fees modestly and capture front-end consumer sales, driving incremental margin expansion in the pharmacy segment over the next 12 to 24 months. The higher-than-expected CMS Medicare rate increase is an underappreciated near-term catalyst: we estimate the 158 basis point difference between initial estimates and final rates could add 120 to 150 basis points to Aetna’s 2026 operating margin, driving 5% to 7% upside to consensus 2026 EPS estimates if management executes on cost control targets. That said, investors should monitor key risks, including potential regulatory scrutiny of pharmacy benefit manager (PBM) pricing practices, higher-than-expected medical cost inflation, and slower-than-projected Oak Street clinic adoption. For long-term investors, the risk-reward profile remains skewed to the upside: the 3.46% dividend yield provides a stable downside floor, while the potential for dividend hikes and a share repurchase program (which management has signaled is under consideration for 2026, once debt leverage falls below 3x EBITDA) could drive multiple re-rating to 14x forward P/E, implying 30%+ total return upside over the next 18 months. Our analysis confirms CVS is a high-conviction value pick for both value and income-oriented investors, with limited downside risk given its defensive healthcare exposure and robust cash generation profile. Disclosure: Analyst James Halley holds long positions in CVS Health. The Motley Fool has issued a bullish recommendation on CVS Health and follows standard public disclosure policies for covered securities. (Word count: 1182)
CVS Health (CVS) – Deep Value Opportunity Amid Underappreciated Integrated Healthcare TransformationEvaluating volatility indices alongside price movements enhances risk awareness. Spikes in implied volatility often precede market corrections, while declining volatility may indicate stabilization, guiding allocation and hedging decisions.Global interconnections necessitate awareness of international events and policy shifts. Developments in one region can propagate through multiple asset classes globally. Recognizing these linkages allows for proactive adjustments and the identification of cross-market opportunities.CVS Health (CVS) – Deep Value Opportunity Amid Underappreciated Integrated Healthcare TransformationObserving trading volume alongside price movements can reveal underlying strength. Volume often confirms or contradicts trends.
